From Germline Variants to Tumor Outcome: GWAS-Based Functional Genomics Prioritizes Colorectal Cancer Susceptibility...

Genome-wide association studies (GWAS) have identified over 200 germline risk loci for colorectal cancer (CRC), yet the causal variants and genes behind most GWAS signals remain unknown and the link between inherited risk and tumor outcome is largely unexplored. Connecting germline single nucleotide polymorphisms (SNPs) to gene expression through expression quantitative trait loci (eQTL) and to clinical outcome is needed to interpret this inherited risk.

We combined CRC GWAS summary data (73,149 cases and 112,467 controls of European ancestry) with GTEx v8 eQTL from colon sigmoid, colon transverse, small intestine terminal ileum, and whole blood, integrating causal transcriptome-wide association study (cTWAS) with SuSiE fine-mapping, Bayesian colocalization, MAGMA SNP-to-gene analysis, and AlphaGenome variant-effect prediction. Prioritized proteins were assessed by western blot. Four experimentally selected regulatory variants were genotyped in HCT116, SW480, RKO, and NCM460 cells; genotype-protein associations were tested across cell-line means, and cis-regulatory effects were assessed by allele-specific expression (ASE) and reference-versus-alternate dual-luciferase assays. Prognostic relevance was evaluated in TCGA colorectal tumors.

cTWAS identified seven genes with posterior inclusion probability (PIP) > 0.50, and colocalization across 78 gene-tissue pairs revealed 20 associations with PP.H4 > 0.80. Four genes showed convergent evidence: SMAD9 (PIP = 0.916, PP.H4 = 0.981), MAP3K2 (PIP = 0.762, PP.H4 = 0.827), FADS1 (PIP = 0.632, PP.H4 = 0.942), and ACTR1B (PIP = 0.566, PP.H4 = 0.994). All four proteins were reduced in CRC cells. Alt-allele dosage was inversely associated with SMAD9 (Pearson r = -0.985, BH-adjusted p = 0.029) and FADS1 protein abundance (r = -0.995, BH-adjusted p = 0.020), but not with MAP3K2 or ACTR1B. Reporter and ASE assays detected the clearest allele-specific effects at SMAD9 and FADS1, whereas MAP3K2 and ACTR1B were null in the tested systems. Lower SMAD9 expression was nominally associated with poorer survival (log - rank p = 0.022 to 0.050), but these associations did not survive Benjamini-Hochberg correction across 12 tests.

Integrating statistical genetics, regulatory prediction, and locus-directed experiments prioritized SMAD9, MAP3K2, FADS1, and ACTR1B as CRC susceptibility genes. Functional evidence was strongest and most directionally coherent for SMAD9, demonstrated allele-specific but context-dependent regulation at FADS1, and placed experimental bounds on the proposed MAP3K2 and ACTR1B mechanisms.